 | Up a level |
Shen, Fei; Jiang, Guanglong; Philips, Santosh; Cantor, Erica; Gardner, Laura; Xue, Gloria; Cunningham, Geneva; Kassem, Nawal; O'Neill, Anne; Cameron, David; Suter, Thomas M; Miller, Kathy D; Sledge, George W; Schneider, Bryan P (2024). Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE. British journal of cancer, 130(8), pp. 1348-1355. Nature Publishing Group 10.1038/s41416-024-02602-0
Goddard, Mark A.; Davies, Zoe G.; Guenat, Solène; Ferguson, Mark J.; Fisher, Jessica C.; Akanni, Adeniran; Ahjokoski, Teija; Anderson, Pippin M.L.; Angeoletto, Fabio; Antoniou, Constantinos; Bates, Adam J.; Barkwith, Andrew; Berland, Adam; Bouch, Christopher J.; Rega-Brodsky, Christine C.; Byrne, Loren B.; Cameron, David; Canavan, Rory; Chapman, Tim; Connop, Stuart; ... (2021). A global horizon scan of the future impacts of robotics and autonomous systems on urban ecosystems. Nature ecology & evolution, 5(2), pp. 219-230. Springer Nature 10.1038/s41559-020-01358-z
Goldhirsch, Aron; Gelber, Richard D.; Piccart-Gebhart, Martine J.; de Azambuja, Evandro; Procter, Marion; Suter, Thomas; Jackisch, Christian; Cameron, David; Weber, Harald A.; Heinzmann, Dominik; Dal Lago, Lissandra; McFadden, Eleanor; Dowsett, Mitch; Untch, Michael; Gianni, Luca; Bell, Richard; Köhne, Claus-Henning; Vindevoghel, Anita; Andersson, Michael; Brunt, A Murray; ... (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 382(9897), pp. 1021-1028. Elsevier 10.1016/S0140-6736(13)61094-6
Cameron, David; Brown, Julia; Dent, Rebecca; Jackisch, Christian; Mackey, John; Pivot, Xavier; Steger, Guenther G.; Suter, Thomas M.; Toi, Masakazu; Parmar, Mahesh; Laeufle, Rita; Im, Young-Hyuck; Romieu, Gilles; Harvey, Vernon; Lipatov, Oleg; Pienkowski, Tadeusz; Cottu, Paul; Chan, Arlene; Im, Seock-Ah; Hall, Peter S.; ... (2013). Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. The lancet oncology, 14(10), pp. 933-942. Elsevier 10.1016/S1470-2045(13)70335-8
